Clinical practice guideline for the treatment of Sjögren’s disease through off-label drug use in China (English edition)

This guideline represents a significant advancement in the management of SJD by introducing structured approaches tailored to patient needs while highlighting areas requiring further research. Key Points • By disaggregating the STAR composite index into its constituent outcome measures, the guideline formulates precise clinical inquiries. • GRADE methodology was used to provide standardized, evidence-based recommendations. • 21 final recommendations for managing glandular, systemic, and organ-specific manifestations in SJD, considering real-world variability. • Prioritizes domestic therapies approaches tailored for Chinese practice.